A5020584133- Lipoproteins and Cardiovascular Health
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Cancer, Lipids, and Metabolism
- Coronary Interventions and Diagnostics
- Atherosclerosis and Cardiovascular Diseases
- Cardiac Imaging and Diagnostics
- Health Systems, Economic Evaluations, Quality of Life
- Cardiac Health and Mental Health
- Genetic factors in colorectal cancer
- Peripheral Artery Disease Management
- Venous Thromboembolism Diagnosis and Management
- Antiplatelet Therapy and Cardiovascular Diseases
- Chronic Disease Management Strategies
- Liver Disease Diagnosis and Treatment
- Fatty Acid Research and Health
- Medical research and treatments
- Health Promotion and Cardiovascular Prevention
- Alcohol Consumption and Health Effects
- Lipid metabolism and disorders
- Natural Products and Biological Research
Hospital Universitario del Tajo
2012-2017
Universidad Alfonso X el Sabio
2017
Hospital Clínico San Carlos
2016
The effect of alirocumab, a PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor, on coronary plaque burden in patients with familial hypercholesterolemia has not been addressed. Our aim was to assess changes and its characteristics after treatment alirocumab by quantification characterization atherosclerotic throughout the tree basis noninvasive analysis computed tomographic angiography asymptomatic subjects receiving optimized stable maximum tolerated statin dose or without...
BACKGROUND: Intensive lipid-lowering therapy may induce coronary atherosclerosis regression. Nevertheless, the factors underlying effect of on disease regression remain poorly characterized. Our aim was to determine which characteristics atherosclerotic plaque are associated with a greater reduction in burden (PB) after treatment alirocumab patients familial hypercholesterolemia. METHODS: The ARCHITECT study (Effect Alirocumab Atherosclerotic Plaque Volume, Architecture and Composition) is...
Los puntajes o escalas de riesgo son ecuaciones diseñadas para determinar la probabilidad ocurrencia un evento.En el caso Cardiología, las cardiovascular tratan calcular sufrir determinado evento en periodo tiempo.Por su amplio uso, cuando nos referimos a riesgo, generalmente estamos hablando los que predicen aparición eventos cardiovasculares relacionados con aterosclerosis.Pero no debemos olvidar existen otras dedicadas otros tipos cardiopatías.Como bien dice artículo ocupa, (1) estas más...
Introduction: Heterozygous familial hypercholesterolemia (HeFH) increases the risk of cardiovascular disease. Traditionally it has been reported that most affected territory is coronary arteries tree. However, there are very few data from large cohorts HeFH and even fewer comparing them with a control population. Hypotesis: To analyse prevalence location disease in individuals their families negative genetic diagnosis study. Methods: Data study, which recruited 3745 aged 18 olderbetween...
“New developments in artificial intelligence may become a very useful future tool for risk stratification, but nowadays good score combined with modulators, as those shown by Professor Daniel A. Siniawski’s team his article, are the scientific basis management of our patients.”
El estudio pivotal REDUCE-IT ha demostrado que el icosapento de etilo es una molécula reduce riesgo sufrir eventos cardiovasculares los pacientes con alto cardiovascular y en tratamiento óptimo estatinas. Por lo tanto, un fármaco del se manera significativa residual estos pacientes. Pero, más allá la publicación inicial REDUCE-IT, amplio abanico diferentes análisis sus datos, han mostrado congruencia este beneficio grupos población. En artículo trata sintetizar evidencia obtenida etilo. The...